Screening for Prostate Cancer

被引:77
作者
Brawley, Otis W. [2 ]
Ankerst, Donna P. [1 ,3 ]
Thompson, Ian M. [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA
[2] Amer Canc Soc, Atlanta, GA 30329 USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA
关键词
MULTICENTER CLINICAL-TRIAL; DIGITAL RECTAL EXAMINATION; RADICAL PROSTATECTOMY; PREVENTION TRIAL; UNITED-STATES; FOLLOW-UP; BLACK-MEN; MODELING APPROACH; ANTIGEN VELOCITY; NG/ML;
D O I
10.3322/caac.20026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s screening with the prostate-specific antigen (PSA) blood test has more-than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of :PSA testing as opposed to other factors, such as improved treatment, has been uncertain.,The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men, undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride. CA Cancer J Clin 2009;59:264-273. (C) 2009 American Cancer Society, Inc.
引用
收藏
页码:264 / 273
页数:10
相关论文
共 76 条
[1]   Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].
Andriole, Gerald L. ;
Grubb, Robert L., III ;
Buys, Saundra S. ;
Chia, David ;
Church, Timothy R. ;
Fouad, Mona N. ;
Gelmann, Edward P. ;
Kvale, Paul A. ;
Reding, Douglas J. ;
Weissfeld, Joel L. ;
Yokochi, Lance A. ;
Crawford, E. David ;
O'Brien, Barbara ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hayes, Richard B. ;
Kramer, Barnett S. ;
Izmirlian, Grant ;
Miller, Anthony B. ;
Pinsky, Paul F. ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319
[2]   Predicting prostate cancer risk through incorporation of prostate cancer gene 3 [J].
Ankerst, Donna Pauler ;
Groskopf, Jack ;
Day, John R. ;
Blase, Amy ;
Rittenhouse, Harry ;
Pollock, Brad H. ;
Tangen, Cathy ;
Parekh, Dipen ;
Leach, Robin J. ;
Thompson, Ian .
JOURNAL OF UROLOGY, 2008, 180 (04) :1303-1308
[3]  
[Anonymous], B J HOPKINS HOSP
[4]  
[Anonymous], 2006, SEER cancer statistics review, 1975-2003
[5]   Tyrol Prostate Cancer Demonstration Project: Early detection, treatment, outcome, incidence and mortality [J].
Bartsch, Georg ;
Horninger, Wolfgang ;
Klocker, Helmut ;
Pelzer, Alexandre ;
Bektic, Jasmin ;
Oberaigner, Wilhelm ;
Schennach, Harald ;
Schaefer, Georg ;
Frauscher, Ferdinand ;
Boniol, Mathieu ;
Severi, Gianluca ;
Robertson, Chris ;
Boyle, Peter .
BJU INTERNATIONAL, 2008, 101 (07) :809-816
[6]   Variations in morbidity after radical prostatectomy. [J].
Begg, CB ;
Riedel, ER ;
Bach, PB ;
Kattan, MW ;
Schrag, D ;
Warren, JL ;
Scardino, PT .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) :1138-1144
[7]   Screening for prostate cancer: have you had your cholesterol measured? [J].
Boyle, P .
BJU INTERNATIONAL, 2003, 92 (03) :191-199
[8]   SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE SPECIFIC ANTIGEN [J].
BRAWER, MK ;
CHETNER, MP ;
BEATIE, J ;
BUCHNER, DM ;
VESSELLA, RL ;
LANGE, PH .
JOURNAL OF UROLOGY, 1992, 147 (03) :841-845
[9]   Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less [J].
Carvalhal, GF ;
Smith, DS ;
Mager, DE ;
Ramos, C ;
Catalona, WJ .
JOURNAL OF UROLOGY, 1999, 161 (03) :835-839
[10]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161